NYSE:AZN - AstraZeneca Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.46 -0.46 (-1.12 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$40.92
Today's Range$39.94 - $40.49
52-Week Range$32.69 - $41.78
Volume8.07 million shs
Average Volume5.51 million shs
Market Capitalization$102.48 billion
P/E Ratio9.45
Dividend Yield2.15%
Beta0.51
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.47 billion
Cash Flow$3.6950 per share
Book Value$6.57 per share

Profitability

Net Income$3.00 billion

Miscellaneous

Employees61,100
Outstanding Shares2,532,896,000
Market Cap$102.48 billion
OptionableOptionable

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semiannual dividend on Friday, February 15th. Stockholders of record on Friday, March 1st will be paid a dividend of $0.95 per share on Wednesday, March 27th. This represents a dividend yield of 4.64%. The ex-dividend date is Thursday, February 28th. This is a boost from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) released its quarterly earnings data on Thursday, February, 14th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.85. The company had revenue of $6.42 billion for the quarter, compared to analysts' expectations of $6.33 billion. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.30 EPS. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, May 17th 2019. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.56. The company issued revenue guidance of high single-digit percentage increase, compared to the consensus revenue estimate of $23.55 billion.AstraZeneca also updated its FY 2019 guidance to $3.50-3.70 EPS.

What price target have analysts set for AZN?

15 Wall Street analysts have issued twelve-month price objectives for AstraZeneca's shares. Their predictions range from $42.00 to $48.00. On average, they anticipate AstraZeneca's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.81%), Bank of America Corp DE (1.00%), Fisher Asset Management LLC (0.59%), Epoch Investment Partners Inc. (0.24%), BlackRock Inc. (0.20%) and Northern Trust Corp (0.13%). View Institutional Ownership Trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Epoch Investment Partners Inc., BlackRock Inc., Canada Pension Plan Investment Board, Raymond James & Associates, Tekla Capital Management LLC, Schafer Cullen Capital Management Inc and Hardman Johnston Global Advisors LLC. View Insider Buying and Selling for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Fisher Asset Management LLC, CIBC Private Wealth Group LLC, Sphera Funds Management LTD., Victory Capital Management Inc., Cookson Peirce & Co. Inc., GQG Partners LLC and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $40.46.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $102.48 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  679 (Vote Outperform)
Underperform Votes:  1,013 (Vote Underperform)
Total Votes:  1,692
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: How Do Mutual Funds Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel